Cancer cytopathology · 2025
Comparative analysis of the World Health Organization Reporting System for Head and Neck Cytopathology and the Milan System for Reporting Salivary Gland Cytopathology.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kowalewski Adam, Borowczak Jędrzej, Choussy Olivier, Lesnik Maria, Badois Nathalie, Klijanienko Jerzy
Аннотация
BACKGROUND: A comparative analysis of the International Academy of Cytology-International Agency for Research on Cancer-World Health Organization Reporting System for Head and Neck Cytopathology (WHO) and the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) was performed.
METHODS: A total of 2218 salivary gland fine-needle aspiration samples collected at the Institut Curie, Paris (1954-2022) were evaluated, with 1356 having histological follow-up. Samples were classified according to the MSRSGC (nondiagnostic [ND], nonneoplastic [NN], atypia of undetermined significance [AUS], benign neoplasm [BN], salivary gland neoplasm of uncertain malignant potential [SUMP], suspicious for malignancy [SM], and malignant [M]) and the WHO system (insufficient/inadequate/nondiagnostic, benign, atypical, neoplasm of uncertain malignant potential [NUMP], suspicious for malignancy [SM], and malignant [M]). The risk of malignancy (ROM) was calculated for each category, and diagnostic performance metrics were assessed.
RESULTS: In the MSRSGC, the ROM was ND, 50% (n = 2); NN, 16.8% (n = 149); AUS (no cases); BN, 4.3% (n = 514); SUMP, 50% (n = 2); SM, 56.1% (n = 66); and M, 98.2% (n = 623). In the WHO system, the ROM was insufficient/inadequate/nondiagnostic, 50% (n = 2); benign, 7.1% (n = 663); atypical (no cases); NUMP, 50% (n = 2); SM, 56.1% (n = 66); and M, 98.2% (n = 623). The WHO's "benign" category, which combines NN and BN, balanced the NN's higher ROM (16.8%) and BN's lower ROM (4.3%) into 7.1%. Excluding the ND and SUMP/NUMP categories, both systems demonstrated high diagnostic performance: sensitivity, 93.3%; specificity, 93.9%; positive predictive value, 94.2%; and negative predictive value, 92.9%.
CONCLUSIONS: Both systems effectively identify malignancy. The WHO system's merger of NN and BN into the benign category streamlines reporting and reduces variability, although it may mask clinically significant differences between nonneoplastic and benign neoplastic lesions.
METHODS: A total of 2218 salivary gland fine-needle aspiration samples collected at the Institut Curie, Paris (1954-2022) were evaluated, with 1356 having histological follow-up. Samples were classified according to the MSRSGC (nondiagnostic [ND], nonneoplastic [NN], atypia of undetermined significance [AUS], benign neoplasm [BN], salivary gland neoplasm of uncertain malignant potential [SUMP], suspicious for malignancy [SM], and malignant [M]) and the WHO system (insufficient/inadequate/nondiagnostic, benign, atypical, neoplasm of uncertain malignant potential [NUMP], suspicious for malignancy [SM], and malignant [M]). The risk of malignancy (ROM) was calculated for each category, and diagnostic performance metrics were assessed.
RESULTS: In the MSRSGC, the ROM was ND, 50% (n = 2); NN, 16.8% (n = 149); AUS (no cases); BN, 4.3% (n = 514); SUMP, 50% (n = 2); SM, 56.1% (n = 66); and M, 98.2% (n = 623). In the WHO system, the ROM was insufficient/inadequate/nondiagnostic, 50% (n = 2); benign, 7.1% (n = 663); atypical (no cases); NUMP, 50% (n = 2); SM, 56.1% (n = 66); and M, 98.2% (n = 623). The WHO's "benign" category, which combines NN and BN, balanced the NN's higher ROM (16.8%) and BN's lower ROM (4.3%) into 7.1%. Excluding the ND and SUMP/NUMP categories, both systems demonstrated high diagnostic performance: sensitivity, 93.3%; specificity, 93.9%; positive predictive value, 94.2%; and negative predictive value, 92.9%.
CONCLUSIONS: Both systems effectively identify malignancy. The WHO system's merger of NN and BN into the benign category streamlines reporting and reduces variability, although it may mask clinically significant differences between nonneoplastic and benign neoplastic lesions.